These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19528235)

  • 1. Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.
    Yang Z; Kondo T; Voorhorst CS; Nabinger SC; Ndong L; Yin F; Chan EM; Yu M; Würstlin O; Kratz CP; Niemeyer CM; Flotho C; Hashino E; Chan RJ
    Mol Cell Biol; 2009 Aug; 29(16):4376-93. PubMed ID: 19528235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival.
    Yang Z; Li Y; Yin F; Chan RJ
    Exp Hematol; 2008 Oct; 36(10):1285-96. PubMed ID: 18640765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Jun is a JNK-independent coactivator of the PU.1 transcription factor.
    Behre G; Whitmarsh AJ; Coghlan MP; Hoang T; Carpenter CL; Zhang DE; Davis RJ; Tenen DG
    J Biol Chem; 1999 Feb; 274(8):4939-46. PubMed ID: 9988737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
    Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
    J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
    Goodwin CB; Yang Z; Yin F; Yu M; Chan RJ
    Haematologica; 2012 Jul; 97(7):1042-7. PubMed ID: 22315502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
    Chan RJ; Leedy MB; Munugalavadla V; Voorhorst CS; Li Y; Yu M; Kapur R
    Blood; 2005 May; 105(9):3737-42. PubMed ID: 15644411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. M-CSF elevates c-Fos and phospho-C/EBPalpha(S21) via ERK whereas G-CSF stimulates SHP2 phosphorylation in marrow progenitors to contribute to myeloid lineage specification.
    Jack GD; Zhang L; Friedman AD
    Blood; 2009 Sep; 114(10):2172-80. PubMed ID: 19587381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
    Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
    Elife; 2022 May; 11():. PubMed ID: 35535491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
    Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
    Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
    Zhang W; Chan RJ; Chen H; Yang Z; He Y; Zhang X; Luo Y; Yin F; Moh A; Miller LC; Payne RM; Zhang ZY; Fu XY; Shou W
    J Biol Chem; 2009 Aug; 284(33):22353-22363. PubMed ID: 19509418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.
    Goodwin CB; Li XJ; Mali RS; Chan G; Kang M; Liu Z; Vanhaesebroeck B; Neel BG; Loh ML; Lannutti BJ; Kapur R; Chan RJ
    Blood; 2014 May; 123(18):2838-42. PubMed ID: 24553178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
    Chan G; Kalaitzidis D; Usenko T; Kutok JL; Yang W; Mohi MG; Neel BG
    Blood; 2009 Apr; 113(18):4414-24. PubMed ID: 19179468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
    Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
    Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
    Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
    Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.
    He C; Peng Z; Zhang D; Guo Y; Liang T; Zhao Y; Yu L; Zhang Q; Chang Z; Xiao Y; Li N; Xue H; Wu S; Zhao ZJ; Zhang C; Chen Y
    Biochem Pharmacol; 2023 Jul; 213():115588. PubMed ID: 37187274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
    De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
    Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.
    Sakashita K; Kato I; Daifu T; Saida S; Hiramatsu H; Nishinaka Y; Ebihara Y; Ma F; Matsuda K; Saito S; Hirabayashi K; Kurata T; Uyen LT; Nakazawa Y; Tsuji K; Heike T; Nakahata T; Koike K
    Leukemia; 2015 Mar; 29(3):606-14. PubMed ID: 25102944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool.
    Zhu HH; Ji K; Alderson N; He Z; Li S; Liu W; Zhang DE; Li L; Feng GS
    Blood; 2011 May; 117(20):5350-61. PubMed ID: 21450902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
    Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
    Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.
    Timeus F; Crescenzio N; Baldassarre G; Doria A; Vallero S; Foglia L; Pagliano S; Rossi C; Silengo MC; Ramenghi U; Fagioli F; Cordero di Montezemolo L; Ferrero GB
    Oncol Rep; 2013 Aug; 30(2):553-9. PubMed ID: 23756559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.